Mark Exley
Company: AgenTus
Job title: VP, Cellular Immunology
Seminars:
Increase Safety by Managing GVHD 1:45 pm
• Review cell types like NK and NKT that have advantages in safety with no GVHD, and increased tolerability • Explore innovative gene editing to overcome GVHD • Review the toxicity risk of incomplete purification of TCR positive cells from the product, which can lead to random pairing and GVHD • Discuss if HLA typing…Read more
day: Track A - Day 2 - 3PM
Chair’s Opening Remarks 10:00 am
day: Day Two
Industry Leader’s Fireside Chat 10:05 am
An executive panel discussion from the C-level leaders of the field to set the scene on allogeneic cell therapy development. Ask your questions live to understand the expert’s thoughts on key topics including gene engineering, cell persistence, ultimate donor source, optimal cryopreservation, and scalable manufacture.Read more
day: Day One
Chair’s Opening Remarks 10:00 am
day: Day One